Return-Path: <inforfqjhu@bizcap.info>
Delivered-To: em-ca-bruceg@em.ca
Received: (qmail 17200 invoked by uid 115); 9 Mar 2005 12:41:45 -0000
Received: from inforfqjhu@bizcap.info by churchill by uid 64011 with qmail-scanner-1.22 
 (clamdscan: 0.75-1. spamassassin: 2.63.  Clear:RC:0(218.82.252.64):. 
 Processed in 7.519142 secs); 09 Mar 2005 12:41:45 -0000
Received: from unknown (HELO bizcap.info) (218.82.252.64)
  by churchill.factcomp.com with SMTP; 9 Mar 2005 12:41:36 -0000
Message-ID: <989C2AA2.B9CF44F@bizcap.info>
Date: Wed, 09 Mar 2005 05:27:52 -1000
Reply-To: "BizCap" <inforfqjhu@bizcap.info>
From: "BizCap" <inforfqjhu@bizcap.info>
User-Agent: Microbod Mail 5.20.2314.1300
X-Accept-Language: en-us
MIME-Version: 1.0
To: <bruceg@em.ca>
Subject: GNBT Fact Sheet
Content-Type: text/html;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 10">
<meta name=Originator content="Microsoft Word 10">
<link rel=File-List
href="Generex%20Biotechnology%20Corporation_files/filelist.xml">
<link rel=Edit-Time-Data
href="Generex%20Biotechnology%20Corporation_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>               </title>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="country-region" downloadurl="http://www.5iantlavalamp.com/"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="place" downloadurl="http://www.5iantlavalamp.com/"/>
<o:SmartTagType namespaceuri="urn:schemas-microsoft-com:office:smarttags"
 name="date"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Brian Conway</o:Author>
  <o:LastAuthor>Brian Conway</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>8</o:TotalTime>
  <o:Created>2005-03-07T12:32:00Z</o:Created>
  <o:LastSaved>2005-03-07T12:32:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>684</o:Words>
  <o:Characters>3905</o:Characters>
  <o:Company>ListGuy.com</o:Company>
  <o:Lines>32</o:Lines>
  <o:Paragraphs>9</o:Paragraphs>
  <o:CharactersWithSpaces>4580</o:CharactersWithSpaces>
  <o:Version>10.2625</o:Version>
 </o:DocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:DrawingGridHorizontalSpacing>6 pt</w:DrawingGridHorizontalSpacing>
  <w:DrawingGridVerticalSpacing>6 pt</w:DrawingGridVerticalSpacing>
  <w:DisplayVerticalDrawingGridEvery>0</w:DisplayVerticalDrawingGridEvery>
  <w:UseMarginsForDrawingGridOrigin/>
  <w:Compatibility>
   <w:SpaceForUL/>
   <w:BalanceSingleByteDoubleByteWidth/>
   <w:DoNotLeaveBackslashAlone/>
   <w:ULTrailSpace/>
   <w:DoNotExpandShiftReturn/>
   <w:WW6BorderRules/>
   <w:FootnoteLayoutLikeWW8/>
   <w:ShapeLayoutLikeWW8/>
   <w:AlignTablesRowByRow/>
   <w:ForgetLastTabAlignment/>
   <w:AutoSpaceLikeWord95/>
   <w:LayoutRawTableWidth/>
   <w:LayoutTableRowsApart/>
   <w:UseWord97LineBreakingRules/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
 </w:WordDocument>
</xml><![endif]--><!--[if !mso]><object
 classid="clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=ieooui></object>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;
	mso-font-alt:"Arial Unicode MS";
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:647 0 0 0 159 0;}
@font-face
	{font-family:"\@SimSun";
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-charset:134;
	mso-generic-font-family:auto;
	mso-font-format:other;
	mso-font-pitch:variable;
	mso-font-signature:1 135135232 16 0 262144 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:SimSun;
	mso-bidi-font-family:"Courier New";
	color:black;}
h1
	{mso-style-next:Normal;
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:14.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:SimSun;
	color:red;
	mso-font-kerning:0pt;
	font-weight:normal;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;
	text-underline:single;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
@page Section1
	{size:8.5in 11.0in;
	margin:1.0in 1.25in 1.0in 1.25in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Times New Roman";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'>

<div class=Section1>

<p class=MsoNormal><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" alt=""
style='width:6in;
 height:36pt'>
 <v:imagedata src="Generex%20Biotechnology%20Corporation_files/image001.png
"
  o:href="http://www.generex.com/images/home/launch-logo1.gif"/>
</v:shape><![endif]--><![if !vml]><img width=576 height=48
src="Generex%20Biotechnology%20Corporation_files/image002.gif"
v:shapes="_x0000_i1025"><![endif]><span
style='mso-spacerun:yes'>              </span><b
style='mso-bidi-font-weight:
normal'><span style='font-size:14.0pt;font-family:Arial'><o:p></o:p></span>
</b></p>

<div style='border:none;border-top:solid windowtext
1.0pt;mso-border-top-alt:
solid windowtext .5pt;padding:6.0pt 0in 0in
0in;margin-left:0in;margin-right:
-.25in'>

<h1 align=center style='text-align:center;border:none;mso-border-top-alt:so
lid windowtext .5pt;
padding:0in;mso-padding-alt:6.0pt 0in 0in 0in'><span class=SpellE><span
style='mso-bidi-font-size:14.0pt;font-family:"Trebuchet
MS";color:windowtext'>Generex</span></span><span
style='mso-bidi-font-size:14.0pt;font-family:"Trebuchet
MS";color:windowtext'>
Biotechnology Corporation.<o:p></o:p></span></h1>

<h1 align=center style='text-align:center;border:none;mso-border-top-alt:so
lid windowtext .5pt;
padding:0in;mso-padding-alt:6.0pt 0in 0in 0in'><span
style='mso-bidi-font-size:
14.0pt;font-family:"Trebuchet MS";color:windowtext'>Investor Fact
Sheet</span><span
style='mso-bidi-font-size:14.0pt'><o:p></o:p></span></h1>

<h1 align=center style='text-align:center;border:none;mso-border-top-alt:so
lid windowtext .5pt;
padding:0in;mso-padding-alt:6.0pt 0in 0in 0in'><!--[if gte vml
1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202"
path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202"
style='position:absolute;
 left:0;text-align:left;margin-left:452pt;margin-top:14.9pt;width:186pt;
 height:198pt;z-index:1;mso-position-horizontal:right'>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
    style='font-size:9.0pt;font-family:Arial'>AT A
GLANCE:<o:p></o:p></span></b></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Symbol <span
    class=SpellE>NasdaqSC</span>: <span style='mso-tab-count:1'>          
</span>GNBT<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Price (</span><st1:date
    Year="2005" Day="4" Month="3"><span style='font-size:9.0pt;font-family:
     Arial'>3/4/05</span></st1:date><span
style='font-size:9.0pt;font-family:
    Arial'>): <span style='mso-tab-count:2'>                     
</span>$0.61<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>52-week
    high/low: <span style='mso-tab-count:1'>             
</span>$0.58/$1.86<o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-size:9.0pt;font-family:Arial'>Av.
    volume (3-mo):<span style='mso-tab-count:1'>             
</span>303,681<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Shares
    outstanding:<span style='mso-tab-count:1'>           </span>34.76
Million<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Float:<span
    style='mso-tab-count:3'>                                     
</span>29.6
    Million<o:p></o:p></span></p>
    <p class=MsoNormal><span style='font-size:9.0pt;font-family:Arial'>%
held
    by insiders:<span style='mso-tab-count:1'>            
</span>14.83%<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Market
    capitalization:<span style='mso-tab-count:1'>          </span>$21.20
Million<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Cash:*<span
    style='mso-tab-count:3'>                                   </span>$1.76
    million<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Long-tem
    Debt:*<span style='mso-tab-count:1'>  </span><span
style='mso-tab-count:
    1'>                </span>$935,000<o:p></o:p></span></p>
    <p class=MsoNormal><span
style='font-size:9.0pt;font-family:Arial'>Revenue**<span
    style='mso-tab-count:2'>                           
</span>$710,000<o:p></o:p></span></p>
    <p class=MsoNormal><i style='mso-bidi-font-style:normal'><span
    style='font-size:9.0pt;font-family:Arial;background:yellow;mso-highligh
t:
    yellow'><o:p>&nbsp;</o:p></span></i></p>
    <p class=MsoNormal><i style='mso-bidi-font-style:normal'><span
    style='font-size:9.0pt;font-family:Arial'>*As of </span></i><st1:date
    Year="2004" Day="31" Month="10"><i
style='mso-bidi-font-style:normal'><span
     style='font-size:9.0pt;font-family:Arial'>10/31/04</span></i></st1:dat
e><i
    style='mso-bidi-font-style:normal'><span
style='font-size:9.0pt;font-family:
    Arial'><o:p></o:p></span></i></p>
    <p class=MsoNormal><i style='mso-bidi-font-style:normal'><span
    style='font-size:9.0pt;font-family:Arial'>**12 months ended
</span></i><st1:date
    Year="2004" Day="31" Month="10"><i
style='mso-bidi-font-style:normal'><span
     style='font-size:9.0pt;font-family:Arial'>10/31/04</span></i></st1:dat
e><i
    style='mso-bidi-font-style:normal'><span
style='font-size:9.0pt;font-family:
    Arial'><o:p></o:p></span></i></p>
    <p class=MsoNormal><span
style='font-size:11.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span
style='font-size:11.0pt;font-family:Arial'><span
    style='mso-tab-count:1'>            </span><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square" side="left"/>
</v:shape><![endif]--><![if !vml]><img width=254 height=270
src="Generex%20Biotechnology%20Corporation_files/image003.gif" align=right
hspace=12
alt="Text Box: AT A GLANCE:&#13;&#10;&#13;&#10;Symbol NasdaqSC: 
GNBT&#13;&#10;Price (3/4/05): 		$0.61&#13;&#10;52-week high/low: 
$0.58/$1.86&#13;&#10;Av. volume (3-mo):	303,681&#13;&#10;&#13;&#10;Shares
outstanding:	34.76 Million&#13;&#10;Float:			29.6 Million&#13;&#10;% held by
insiders:	14.83%&#13;&#10;Market capitalization:	$21.20
Million&#13;&#10;&#13;&#10;Cash:*			$1.76 million&#13;&#10;Long-tem Debt:*	
$935,000&#13;&#10;Revenue**		$710,000&#13;&#10;&#13;&#10;*As of
10/31/04&#13;&#10;**12 months ended 10/31/04&#13;&#10;&#13;&#10;	&#13;&#10;"
v:shapes="_x0000_s1026"><![endif]></h1>

<h1 style='border:none;mso-border-top-alt:solid windowtext
5pt;padding:0in;
mso-padding-alt:6.0pt 0in 0in 0in'><b
style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;font-family:Arial;color:windowtext;mso-no-proof:yes
'>Insulin
Without Pain, Ready for Market</span></b><b
style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;font-family:Arial;mso-no-proof:yes'>
</span></b><span
style='font-size:11.0pt;font-family:"Trebuchet
MS";color:windowtext'><o:p></o:p></span></h1>

</div>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>-- <span
class=SpellE>Generex</span>
Biotechnology (<span class=SpellE>NasdaqSC</span>: GNBT) has developed
Oral-<span
class=SpellE>lyn</span>™, an oral insulin spray for the treatment of
diabetes,
thereby replacing insulin injections. <o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>-- After 10 years of
development, Oral-<span
class=SpellE>lyn</span>™ has been found to be as effective as injected
insulin and
is ready for commercialization.<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>-- Sales could start as early as
the
first half of 2005 in </span></b><st1:place><b style='mso-bidi-font-weight:
 normal'><span style='font-size:10.0pt;font-family:Arial'>South
America</span></b></st1:place><b
style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:
Arial'>. Canada and Europe is the next target market, with
</span></b><st1:country-region><st1:place><b
  style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:
  Arial'>U.S.</span></b></st1:place></st1:country-region><b
style='mso-bidi-font-weight:
normal'><span style='font-size:10.0pt;font-family:Arial'> and
</span></b><st1:place><b
 style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:
 Arial'>Europe</span></b></st1:place><b
style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'> to
follow.<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>-- Diabetes is growing at
epidemic
rates. Hundreds of millions suffer from type 1, type 2 or pre-diabetes.
Even
modest penetration of the worldwide diabetes market would translate into
revenues
in the billion-dollar range.<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>-- <span
class=SpellE>Generex’s</span>
delivery system, <span class=SpellE>RapidMist</span>™, has the potential to
replace
injected drugs, including morphine, <span class=SpellE>fentanyl</span>,
heparin
and flu vaccine.<o:p></o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'>Why Buy Now</span></b><span
style='font-size:10.0pt;font-family:Arial'><o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial'><o:p>&n
bsp;</o:p></span></p>

<p class=MsoNormal><span class=SpellE><span
style='font-size:10.0pt;font-family:
Arial'>Generex</span></span><span
style='font-size:10.0pt;font-family:Arial'>
Biotechnology is a Toronto-based, Delaware Corporation with a market-ready
solution to a central challenge in diabetes treatment – ending the pain and
hassle of insulin injections. Ever since scientists early in the 20th
century
learned that diabetes was caused by the body’s inability to produce a
normal
supply of insulin, patients have had to administer insulin by injection.
Alternatives
that have been developed in recent years – pumps or needle-less “pens” –
are
still invasive and/or expensive. Pharmaceutical companies have tried to
develop
a truly non-invasive insulin product that is pain-free, easy to use and
free from
serious side effects.<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial'><o:p>&n
bsp;</o:p></span></p>

<p class=MsoNormal><span style='font-size:10.0pt;font-family:Arial'>Among
today’s competing technologies, only Oral-<span class=SpellE>lyn</span>™,
an
insulin spray to treatment diabetes, meets all those tests. After 10 years
of
development, Oral-<span class=SpellE>lyn</span>™ is ready for market and is
set
to produce enormous revenue growth for the company. <span
class=SpellE>Generex</span>
is little known outside a small community of investors focused on drug
delivery
and diabetes treatment. In the next few months, however, the expected
commercial
entry of Oral-<span class=SpellE>lyn</span>™ in </span><st1:place><span
 style='font-size:10.0pt;font-family:Arial'>South
America</span></st1:place><span
style='font-size:10.0pt;font-family:Arial'> could raise <span
class=SpellE>Generex’s</span>
profile sharply, with a commensurate rise in their share price. Small
companies
in drug and medical-device development are, of course, inherently high-risk
investments. But aggressive investors who take an early stake in these
firms
can profit several times over. <span class=SpellE>Generex</span> has the
profile of being one such potential winner.<o:p></o:p></span></p>

<p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
style='font-size:10.0pt;font-family:Arial'><o:p>&nbsp;</o:p></span></b></p>

<p class=MsoNormal><span style='font-size:7.0pt;font-family:Arial'><o:p>&nb
sp;</o:p></span></p>

<div style='border:none;border-top:solid windowtext
1.0pt;mso-border-top-alt:
solid windowtext .5pt;padding:1.0pt 0in 0in 0in'>

<p class=MsoNormal style='text-align:justify;border:none;mso-border-top-alt
:
solid windowtext .5pt;padding:0in;mso-padding-alt:1.0pt 0in 0in 0in'><span
style='font-size:7.0pt;font-family:"Trebuchet MS"'>Readers are advised that
this Investor Fact Sheet is intended for informational use only.<span
style='mso-spacerun:yes'>  </span>Anyone interested in obtaining more
detailed
information about the Company should contact <span
class=SpellE>Generex</span>
Biotechnology (<span class=SpellE>Generex</span>) or Investor Relations
International (IRI). This Investment Profile was developed as part of an
overall investor relations program with IRI.<span
style='mso-spacerun:yes'> 
</span>IRI has been retained by <span class=SpellE>Generex</span> to
provide
investor relations advisory services, for which IRI receives compensation
in the
form of cash. This Investment Fact Sheet is intended solely for
informational
purposes and is not to be construed as an offer to sell or the solicitation
of
an offer to buy the Company's stock. This Investment Fact Sheet is based
upon
information available to the public, as well as other information from
sources
deemed reliable, but is not guaranteed as being accurate nor does it
purport to
be complete. This Investment Fact Sheet may contain forward-looking
statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements are subject to a variety of risks and
uncertainties,
many of which are beyond <span class=SpellE>Generex’s</span> control, which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. For additional information
regarding
these and other risks faced by the Company, visit the company’s website at
<a
href="http://www.generex.com/">www.generex.com</a>. </span><span
style='font-size:7.0pt;font-family:Arial'><o:p></o:p></span></p>

</div>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal><span style='font-size:10.0pt'>This message is sent to
you
in compliance with the Federal CAN-Spam Bill and the Electronic Commerce
(EC
Directive) Regulations of 2004. This is a commercial email which includes
an
unsubscribe method for remove processing as mandated by law. Footer also
includes
the sender's information. <span class=SpellE>BizCap.info</span> <span
class=SpellE>p.o</span>. box 155 Sugarloaf, NY. 10981 To be excluded from
future mailings, please reply to this email with &quot;<span
class=SpellE>rem</span>&quot;
in the subject line.</span></p>

</div>

</body>

</html>


